Gene Expression Data Could Guide Search for Anti-Aging Drugs
Finding drugs that modestly slow aging often begins with screening large compound libraries, so researchers need ways to prioritize candidates. This paper reviews transcriptomic strategies, including a reversal approach that identifies drugs opposing age-related gene expression changes. Most geroprotectors found so far act through well-known pathways such as mTOR, AMPK, and HDAC, highlighting the need for broader discovery methods.
Screens in invertebrates have yielded hundreds of compounds that extend lifespan, yet only a small share work across species. Most fall into familiar classes: mTOR inhibitors, AMPK activators, and HDAC inhibitors, which affect broad cellular processes and may cause wide-ranging effects.
Transcriptomic methods offer alternatives. The reversal approach seeks drugs that oppose aging-related expression shifts, yielding oridonin; the mimic approach compares drug profiles against established longevity interventions, identifying allantoin and rilmenidine. Using worms and mice, the authors analyzed coexpression modules, found adaptive aging changes, and identified seven new geroprotectors from module signatures.
If transcriptomic signatures help prioritize compounds, drug developers and research funders could allocate screening resources differently, potentially accelerating early-stage anti-aging research. Patients and older adults might eventually benefit if new geroprotectors reach trials, though any clinical impact may be years away and uncertain. Broader discovery could reduce reliance on a few pathways, but safety and efficacy in humans remain unresolved.